A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.
- 1 January 1999
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 15 (1) , 23-37
- https://doi.org/10.2165/00019053-199915001-00003
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Lamivudine Reduces Healthcare Resource Use when Added to Zidovudine-Containing Regimens in Patients with HIV InfectionPharmacoEconomics, 1999
- The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.1998
- Antiretroviral Therapy for HIV Infection in 1998JAMA, 1998
- Modelling the Potential Economic Impact of Viral Load???Driven Triple Drug Combination Antiretroviral TherapyPharmacoEconomics, 1998
- Design of the trial of Org 10172 in acute stroke treatment (TOAST)Controlled Clinical Trials, 1997
- Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.PharmacoEconomics, 1997
- Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.1997
- Costs to Medicaid of Advancing Immunosuppression in an Urban HIV-Infected Patient Population in MarylandJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/??l in 5 European CountriesPharmacoEconomics, 1994
- On the decision rules of cost-effectiveness analysisJournal of Health Economics, 1993